 LA JOLLA, Calif., June 02, 2021 GLOBE NEWSWIRE -- Artelo Biosciences, Inc. NASDAQ: ARTL , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that management will present at the LD Micro Invitational XI investor conference taking place virtually June 8-10, 2021. 